Approval · Notice of Compliance 29035 · 2022
TEVA-LENALIDOMIDE: Notice of Compliance 29035
Issued September 22, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 29035
- Date
- September 22, 2022
- Company
- Teva Canada LimitedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Abbreviated New Drug Submission (ANDS)
- Submission class
- Other
- Canadian reference product
- REVLIMID (Celgene Inc)
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| TEVA-LENALIDOMIDE | 02530864 | Cancelled Pre Market |
| TEVA-LENALIDOMIDE | 02530872 | Cancelled Pre Market |
| TEVA-LENALIDOMIDE | 02530880 | Cancelled Pre Market |
| TEVA-LENALIDOMIDE | 02530899 | Cancelled Pre Market |
| TEVA-LENALIDOMIDE | 02530902 | Cancelled Pre Market |
| TEVA-LENALIDOMIDE | 02530910 | Cancelled Pre Market |
Medicinal ingredients
- LENALIDOMIDE HYDROCHLORIDE 2.5 MG per CAP
- LENALIDOMIDE HYDROCHLORIDE 5 MG per CAP
- LENALIDOMIDE HYDROCHLORIDE 10 MG per CAP
- LENALIDOMIDE HYDROCHLORIDE 15 MG per CAP
- LENALIDOMIDE HYDROCHLORIDE 20 MG per CAP
- LENALIDOMIDE HYDROCHLORIDE 25 MG per CAP